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In March 2013, a novel avian-origin inﬂuenza A (H7N9) virus was isolated from throat swabs of 2 patients
at the Fifth People’s Hospital of Shanghai, China. Subsequently, 4 more patients infected by H7N9 were
identiﬁed. Of the 6 patients, 4 died of acute respiratory distress syndrome. Here, we report the ﬁrst case
of a patient who recovered from pneumonia induced by H7N9 infection. The patient presented with
fever, cough, and blood in sputum. Laboratory tests showed a low level of leukocytes, hypoxaemia,
and increased levels of creatine kinase and lactate dehydrogenase. Imaging showed multiple areas of
segmental ground-glass opacity in the right lung. Oseltamivir and antibiotics were administered. Sup-
plemental oxygen helped relieve symptoms. Approximately 2 weeks after treatment, the patient ﬁnally
recovered. A follow-up chest computed tomography scan taken 8 weeks later revealed that the ground-
glass opacity was clearly absorbed. Therefore, timely intervention with oseltamivir and supplemental
oxygen may be very important in the treatment of H7N9 infection.
Crown Copyright  2013 Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
Cases of human infection with avian-origin H7 avian inﬂuenza
viruses have been previously documented [1e4], but infection
with an N9 subtype inﬂuenza virus has not been reported in
humans. Human H7 inﬂuenza infections are generallymild, causing
conjunctivitis or modest respiratory symptoms. In March 2013, a
novel avian-origin inﬂuenza A (H7N9) virus was identiﬁed in throat
swab specimens obtained from 2 patients who died of severe
pneumonia in our hospital [5]. Shortly thereafter, we discovered 4
more patients infected with H7N9. Finally, 4 of the 6 patients died,
while 2 patients recovered. To the best of our knowledge, this is the
ﬁrst report of a patient who recovered from pneumonia induced by
H7N9 infection.
2. Case report
A 40-year-old man who complained of ‘fever, cough, and blood
in sputum persisting for 3 days’ was admitted to the Fifth People’s
Hospital of Shanghai, Fudan University, on 6 March 2013. He had a
smoking history for 20 years (approximately 800 cigarettes/year)
with an unremarkable medical history.in this study.
evier Ltd. Open access under CC BY licOn admission (6 March), physical examination showed a stable
respiratory rate (20/min), normal blood pressure (130/80 mmHg),
tachycardia (heart rate, 120 bpm), and fever (body temperature,
39 C). Moist rales were heard in the lower lobe of the left lung.
Arterial blood gas analysis revealed hypoxaemia (arterial oxygen,
64mmHg). Blood test showed normal white blood cell (WBC) count
(4.99  109/L), while the percentage of neutrophils (78.4%) was
higher than the normal range. Chest-CT showed multiple areas of
segmental ground-glass opacity in themiddle and lower lobe of the
right lungwith clear signs of air bronchogram; the left lung showed
no pathological abnormality, and there were no signs of enlarged
mediastinal lymph nodes (Fig. 1a). The patient was initially treated
by moxiﬂoxacin and oxygen treatment (nasal catheter oxygen
inhalation with an oxygen ﬂow rate of 4 L/min).
On the day after admission (7 March), laboratory tests showed
elevated enzyme levels: creatine kinase (CK), 984 U/L, creatine ki-
nase isoenzymes (CK-MB), 20 U/L, lactate dehydrogenase (LDH),
498 U/L, alanine aminotransferase (ALT), 46 U/L, and aspartate
aminotransferase (AST), 51 U/L. The patient’s body temperature did
not return to normal. We continued to obverse himwhile providing
physical cooling.
On day 2 after admission (8 March), the patient’s clinical symp-
toms were not resolved, and his body temperature increased to
39.7 C. Hypoxaemia persisted after inhaling oxygen (arterial blood
gas analysis: pH 7.5; arterial partial pressure of carbon dioxide,
30 mmHg; arterial partial pressure of oxygen, 64 mmHg) (Table 1).
We replaced moxiﬂoxacinwith meropenem as antibacterial therapy.ense.
Fig. 1. Imaging changes in the ﬁrst case of recovery from H7N9. Panel a (6 March) showed multiple segmental ground-glass opacity lesions in the middle and lower lobe of the right
lung with clear signs of air bronchogram. The left lung showed no pathological abnormalities, and no signs of mediastinal lymph node enlargement were seen. Panel b (10 March)
showed that the opacities had become more conﬂuent and dense, revealing a progressing inﬂammatory response. Panel c (17 March) showed that inﬂammation was absorbed
compared to the ﬁndings from 10 March. Panel d (24 April) showed that inﬂammation was clearly further absorbed compared to previous ﬁndings.
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symptoms were not resolved. A blood test revealed a decreased
WBC count of 3.38  109/L, and increased levels of ALT of 217 U/L
and AST of 160 U/L (Table 1). Chest-computed tomography (CT)
showed that the opacities had become more conﬂuent and dense,
with a new large ﬁeld of opacities in the right lung and patchy
opacities in the lower lobe of the left lung. Inﬂammation had also
clearly progressed (Fig. 1b). On the same day, a 27-year-old male
patient died of progressive pneumonia and acute respiratory
distress syndrome. After we discussed the similar features of the 2Table 1
Laboratory data of the ﬁrst case of recovery from H7N9.
Date 6 Mar 7 Mar 8 Mar 10 Mar 11 Mar
WBC (109/L) NA 4.49 4.24 3.38Y NA
Lym (109/L) NA 1.08 0.94 1.17 NA
PLT (109/L) NA 104 113 144 NA
LDH (U/L) NA 498[ NA NA NA
CK (U/L) NA 984[ NA NA NA
CK-MB (U/L) NA 20 47 35 NA
ALT (U/L) NA 46 54[ 217[ NA
AST (U/L) NA 51[ 71[ 160[ NA
pH 7.51 NA 7.5y NA 7.42
PaCO2 (mmHg) 28 NA 30y NA 35
PaO2 (mmHg) 64Y NA 64Yy NA 113
WBC: white blood cells, Lym: lymphocyte, PLT: platelets, LDH: lactate dehydrogenase, CK
AST: aspartate aminotransferase, PaO2: arterial partial pressure of oxygen, PaCO2: arter
y After nasal catheter oxygen inhalation with oxygen ﬂow 4 L/min.
Y Lower than reference value.
[ Higher than reference value.cases and took ﬂu season into account, oseltamivir and amantadine
were administered as antiviral therapy.
On day 11 (17 March), the patient’s clinical symptoms had
resolved except for occasional cough and blood in sputum. The
patient’s body temperature had decreased to within the normal
range. SpO2 rose to 98%. Chest-CT scanning showed that inﬂam-
mation was absorbed compared to the ﬁndings from 10 March,
but irregular opacities remained in the mid-lower lobe of the
right lung (Fig. 1c). On 18 March, the patient was discharged from
the hospital.13 Mar 18 Mar 30 Mar 23 Apr Normal range
7.77 6.23 9.86 7.18 4.0e10.0
1.51 1.71 3.92 2.92 1.0e4.0
232 370 181 201 100e400
NA 263 NA NA 135e215
NA NA NA NA 24e192
33 NA NA NA 0e25
155[ 100[ 81[ 39 0e55
54[ 34 34 25 0e50
NA NA NA NA 7.35e7.45
NA NA NA NA 35e45
NA NA NA NA 83e108
: creatine kinase, CK-MB: creatine kinase isoenzyme, ALT: alanine aminotransferase,
ial partial pressure of carbon dioxide.
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clearly showed that inﬂammation was further absorbed compared
to earlier ﬁndings (Fig.1d). Blood cell counts and liver function tests
were within the normal ranges (Table 1).
We tested the patient’s pulmonary function during his hospi-
talization (11 March) and found restricted pulmonary ventilation
disorder (FEV1%:45%, FEV1/FEVC%:102%, FVC%:48) and diffuse
dysfunction (DLCO%:49%). Approximately 5 weeks after the patient
was discharged from the hospital (24 April), pulmonary function
tests became normal (FEV1%: 94%, FEV1/FVC%:114%, FVC%:86%.
DLCO%:85).3. Discussion
To the best of our knowledge, this is the ﬁrst report of a pa-
tient who recovered from pneumonia caused by a lethal case of
human avian-origin inﬂuenza virus H7N9. H7N9 virus was not
found in the throat swab specimens obtained from this patient
on 8 March; however, speciﬁc viral antibody IgG was detected in
recovery serum (IgG:1:40) at the Chinese Centre for Disease
Control and Prevention on 13 April. Therefore, this patient was
conﬁrmed to be infected with H7N9. The patient complained of
fever, cough, and blood in sputum and presented with decreased
WBC count after virus infection. Blood test showed increased
enzyme levels (LDH, CK, CK-MB, ALT, and AST), with especially
high levels of LDH and CK. Chest-CT revealed ground glass
changes, and hypoxaemia was noticed after admission, suggest-
ing high H7N9 viral virulence.
Antibacterial therapy did not yield positive results in the rapid
progression of the disease. We considered the possibility of inﬂu-
enza virus infection. Oseltamivir and amantadine were adminis-
tered as antiviral therapy on day 4 after admission. Althoughwe did
not use oseltamivir and amantadine in the ﬁrst 48 h, clinical
symptoms had signiﬁcantly remitted. However, a 27-year-old male
patient who was also positive for H7N9 died after active treatment
for 6 days. Therefore, the prognosis of human H7N9 infection may
be related to the viral load of H7N9, autoimmunity, and interven-
tion time. The 27-year old patient was a pork trader in the live-
poultry market and was admitted to the hospital almost a week
after illness onset, during which time he was also actively positive
for hepatitis B.
The pathogenesis of human avian-origin inﬂuenza A (H7N9)
virus infection is unknown. It has been previously proposed that
highly pathogenic avian inﬂuenza virus infections lead to the
induction of a strong inﬂammatory response, characterized by
elevated serum levels of cytokines and chemokineses [6]. This
view may be a breakthrough for us to explore the pathogenesis of
avian-origin inﬂuenza virus in human. In H5N1 and H9N2 inﬂu-
enza viruses, neuraminidase stalk length was associated with
virulence and pathogenesis in mice [7,8]. In addition, a mutation
at position 627 of the gene encoding the PB2 protein, which is
associated with the outcome of infection in mice [9], was found to
be associated with the virus [1]. We speculated that this mutation
may contribute to the rapid progression of the disease in patients.
An epidemiological survey on H7N9 in China revealed that among
82 patients, 76% had a history of exposure to poultry [10].
Although the patient is this report denied a history of exposure to
poultry, H7N9 virus was found in the poultry of 2 neighbouring
markets. No symptoms were observed in the hospital among
doctors and nurses caring for the patient, suggesting that the
disease does not readily spread. Moreover, limited human-to-
human transmission was observed in the H7 outbreak in the
Netherlands in 2003 [3]. However, we do not exclude the possi-
bility of human-to-human transmission.4. Conclusion
In conclusion, avian inﬂuenza H7N9 infection remains a new
disease entity. Factors such as clinical symptoms with fever and
cough; laboratory tests with low levels of leukocytes, hypoxaemia,
and increased enzyme levels; and chest-CT showing multiple areas
of segmental ground-glass opacity as well as a history of direct
contact with poultry are criteria for the diagnosis of avian inﬂuenza
H7N9 infection. Furthermore, timely intervention with oseltamivir
and supplemental oxygen may be very important therapies for
H7N9 infection. Future studies are needed to further characterize
the disease, as well as elucidate the molecular and biological
characteristics of patients infected with H7N9 and their prognostic
signiﬁcance, so as to devise optimal treatment strategies.
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